Irinotecan is an intravenous anti-cancer medicine used mainly for colon cancer and also for small cell lung cancer in combination regimens. It belongs to the topoisomerase inhibitor family and works through topoisomerase I blockade with downstream DNA damage and tumor cell death. It was approved for medical use in the United States in 1996.
A first-in-human T-cell therapy showed lasting benefit in children with DIPG and relapsed CNS tumors, while a preclinical mRNA vaccine reduced neuroblastoma tumor size by 70%. Aneuploidy predicted response to olaparib plus irinotecan.
AI identified rectal cancer patients who benefit from adding irinotecan to chemoradiotherapy, cutting recurrence and death risk. Separate research finds most online AI-cancer information is low quality and too complex for patients.
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
Pfizer reported positive topline PFS results for encorafenib plus cetuximab and FOLFIRI in BRAF V600E-mutant mCRC from BREAKWATER cohort 3. The regimen showed significant PFS improvement and clinically meaningful OS benefit, with no new safety signals.
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
Oncolytics Biotech launches Phase 2 trial of pelareorep immunotherapy in metastatic colorectal cancer, following Fast Track Designation and promising earlier results showing 27-month median survival.
Pfizer announced positive progression-free survival results from the BREAKWATER trial evaluating Braftovi in combination with cetuximab and Folfiri in previously untreated metastatic colorectal cancer patients with BRAF V600E mutation.
Alphamab Oncology dosed the first patient in its Phase III trial of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, for HER2-positive advanced colorectal cancer on February 14, 2026.
Alphamab Oncology has dosed the first patient in a Phase III study of JSKN003, a biparatopic HER2-targeting ADC, for HER2-positive advanced colorectal cancer. The drug demonstrated a 68.8% response rate in earlier trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775287 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07748611 |
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07722754 |
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07712094 |
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07705919 |
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07678593 |
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07662031 |
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07649655 |
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07621718 |
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) |
RECRUITING | PHASE3 |
| NCT07619313 |
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer |
RECRUITING | PHASE1 |
